What is Benicar HCT, and how does it work?
Benicar HCT is a prescription medication containing a combination of olmesartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a diuretic). It is primarily used to treat high blood pressure (hypertension) in adults [1]. By combining olmesartan and hydrochlorothiazide, Benicar HCT works to lower blood pressure through two mechanisms: blocking the action of a natural chemical that narrows blood vessels and increasing the amount of urine produced to rid the body of excess water and salt.
Side effects and patient concerns
Like all medications, Benicar HCT can cause side effects. Common side effects reported include dizziness, fatigue, and headache. Less common but serious side effects include stomach problems, elevated potassium levels, and allergic reactions [2]. It is crucial for patients to disclose any medical history, especially kidney disease, liver disease, or gout, to their healthcare provider before taking Benicar HCT.
Difference between Benicar HCT and Benicar
The main difference between Benicar HCT and Benicar lies in their mechanism of action. While Benicar is an angiotensin II receptor antagonist that only lowers blood pressure, Benicar HCT combines this action with the diuretic effect of hydrochlorothiazide. Therefore, Benicar HCT is often used when there is a need for both mechanisms to effectively manage high blood pressure [3].
Patent and exclusivity information
Benicar HCT was initially developed and released by Daiichi Sankyo but is now marketed in the United States by Sankyo Pharma Inc. and distributed by Daiichi Sankyo Inc. The original patent for Benicar expired in 2011, but additional patents for the formulation expired in 2014. However, the combination patent for Benicar HCT is set to expire in 2026 due to patent expiration and generic competition [4].
Why are some companies challenging the patent?
Generic manufacturers, including Teva Pharmaceuticals and Mylan Pharmaceuticals, have received approval from the U.S. Food and Drug Administration (FDA) to launch generic or bioequivalent versions of Benicar HCT. These companies may be challenging the patent due to disagreements over licensing agreements, market exclusivity, or potential patent invalidation [5].
Pricing and availability of generic options
Generic or bioequivalent versions of Benicar HCT may offer lower prices than the branded product. Prices can vary depending on the manufacturer, dosage, and quantity dispensed. Consumers can check prices at pharmacies like CVS, Walmart, and online retailers. However, please consult your healthcare provider before switching between any branded or generic medications.
Sources:
[1] FDA.gov: Olmesartan-Hydrochlorothiazide - Benicar HCT
[2] Drugs.com: Benicar HCT side effects
[3] RxList: Benicar HCT vs Benicar
[4] DrugPatentWatch.com: Benicar HCT patents
[5] BloombergLaw.com: Generic companies challenging patents on multiple medications